Aceso Life Science Group Limited (0474.HK)
HKD 0.05
(0.0%)
HKD 0.05
(0.0%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -200 Million | 222 Million | 316 Million | 179 Million | -356.31 Million | -83.92 Million |
| Net Income | -462 Million | -213 Million | -555 Million | -323 Million | -267.22 Million | -480.57 Million |
| Depreciation & Amortization | 21 Million | 52 Million | 68 Million | 63 Million | 56.9 Million | 58.36 Million |
| Deferred income taxes | - | 138 Million | 449 Million | 187 Million | 163.39 Million | 300.89 Million |
| Stock-based compensation | - | 3 Million | 7 Million | 49 Million | 2 Million | 5 Million |
| Change in working capital | -107 Million | 132 Million | 214 Million | 48 Million | -397.48 Million | -94.89 Million |
| Other non-cash items | 473 Million | 110 Million | 133 Million | 155 Million | 84.45 Million | 127.29 Million |
| Investing Cash Flow | 472 Million | -120 Million | -441 Million | -10 Million | 994.29 Million | -1.24 Billion |
| Investments in PPE | -11 Million | -47 Million | -57 Million | -15 Million | -36.18 Million | -70.73 Million |
| Acquisitions | 5 Million | 17 Million | 4 Million | 4 Million | 18.24 Million | 95.76 Million |
| Investment purchases | - | -112 Million | -76 Million | -3 Million | -320 Million | -13.24 Million |
| Sales/Maturities of investments | 450 Million | 10 Million | 41 Million | 4 Million | 1.43 Billion | 112.98 Million |
| Other Investing Activities | 33 Million | 12 Million | -353 Million | 15 Million | -99.77 Million | -1.37 Billion |
| Financing Cash Flow | -161 Million | -98 Million | 126 Million | -375 Million | -521.79 Million | 824.14 Million |
| Debt repayment | -145 Million | -599 Million | -574 Million | -682 Million | -561.42 Million | -1.03 Billion |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | -9 Million | -5 Million | - | - | - |
| Common Stock Issuance | - | - | - | 217 Million | - | - |
| Other Financing Activities | 420 Million | 510 Million | 705 Million | 90 Million | 39.63 Million | 1.86 Billion |
| Accounts receivables | -78 Million | 114 Million | 223 Million | 67 Million | -300.61 Million | 83.74 Million |
| Accounts payables | -7 Million | 7 Million | 2 Million | -14 Million | 22.35 Million | -61.76 Million |
| Inventory | 2 Million | 4 Million | 9 Million | 1 Million | 2.67 Million | 21.9 Million |
| Other working capital | -24 Million | 7 Million | -20 Million | -6 Million | -121.89 Million | -138.78 Million |
| Cash at beginning of period | 217 Million | 195 Million | 198 Million | 382 Million | 267.04 Million | 781.43 Million |
| Cash at end of period | 369 Million | 187 Million | 195 Million | 198 Million | 381.72 Million | 267.04 Million |
| Capital Expenditure | -11 Million | -47 Million | -57 Million | -15 Million | -36.18 Million | -70.73 Million |
| Effect of forex changes on cash | 8 Million | -12 Million | -4 Million | 12 Million | -1.5 Million | -7.2 Million |
| Net cash flow / Change in cash | 152 Million | -8 Million | -3 Million | -184 Million | 114.68 Million | -514.39 Million |
| Free Cash Flow | -211 Million | 175 Million | 259 Million | 164 Million | -392.49 Million | -154.65 Million |
| Breakdown | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 FY |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -127.5 Million | -462 Million | -127.5 Million | -207 Million | -103.5 Million | -213 Million |
| Depreciation & Amortization | 8 Million | 21 Million | 8 Million | 34 Million | 17 Million | 52 Million |
| Deferred income taxes | - | - | - | - | - | 138 Million |
| Stock-based compensation | -500 Thousand | - | -500 Thousand | 500 Thousand | 500 Thousand | 3 Million |
| Change in working capital | -50 Million | -107 Million | -50 Million | - | - | 132 Million |
| Other non-cash items | 136 Million | 473 Million | 136 Million | 200 Million | 101.5 Million | 110 Million |
| Investing Cash Flow | 14 Million | 472 Million | 14 Million | 45 Million | 23.5 Million | -120 Million |
| Investments in PPE | 3.5 Million | -11 Million | 3.5 Million | -18 Million | -9 Million | -47 Million |
| Acquisitions | - | 5 Million | - | - | - | 17 Million |
| Investment purchases | - | - | - | - | - | -112 Million |
| Sales/Maturities of investments | 445 Million | 450 Million | - | 5 Million | - | 10 Million |
| Other Investing Activities | 10.5 Million | 33 Million | 10.5 Million | 58 Million | 32.5 Million | 12 Million |
| Financing Cash Flow | 127 Million | -161 Million | 127 Million | -63 Million | -68.5 Million | -98 Million |
| Debt repayment | -89 Million | -145 Million | - | -56 Million | - | -599 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | -9 Million |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | 127 Million | 420 Million | 127 Million | -68.5 Million | -68.5 Million | 510 Million |
| Accounts receivables | - | -78 Million | - | - | - | 114 Million |
| Accounts payables | - | -7 Million | - | - | - | 7 Million |
| Inventory | 1 Million | 2 Million | 1 Million | - | - | 4 Million |
| Other working capital | -51 Million | -24 Million | -51 Million | - | - | 7 Million |
| Cash at beginning of period | 141 Million | 217 Million | - | 217 Million | - | 195 Million |
| Cash at end of period | 369 Million | 369 Million | 110 Million | 141 Million | -28.5 Million | 187 Million |
| Capital Expenditure | 3.5 Million | -11 Million | 3.5 Million | -18 Million | -9 Million | -47 Million |
| Effect of forex changes on cash | 3 Million | 8 Million | 3 Million | 1 Million | 1 Million | -12 Million |
| Net cash flow / Change in cash | 228 Million | 152 Million | 110 Million | -76 Million | -28.5 Million | -8 Million |
| Free Cash Flow | -30.5 Million | -211 Million | -30.5 Million | -59 Million | 6.5 Million | 175 Million |
ERL
DWGL
0HXW
EASTRED
CXSE3
KNIT